Veeva Systems Inc

Veeva Systems boosts its life‑sciences edge as 13 of the largest biopharma firms adopt its Link Key People platform, adding AI tools and APIs that standardize engagement data for faster decision‑making and future growth.

Veeva Systems faces a mixed week: JPMorgan Healthcare Conference boost, but Goldman Sachs downgrade over AI competition and valuation concerns—can the cloud‑native life‑sciences leader sustain growth?

Veeva Systems accelerates its life‑science software leadership with a deep BioMarin partnership and new environmental monitoring tool, driving faster, compliant pharma operations.

Veeva Systems launches a $2 billion share buyback, boosting EPS and reinforcing its cash‑rich, cloud‑based platform for life‑science firms.

Veeva Systems’ cloud‑software for life sciences shows resilience amid AI‑shaken markets, offering investors a high‑growth option in health‑tech.

Veeva Systems: leading cloud‑based health‑tech stock with solid growth, high PE, and global reach—ideal for investors eyeing life‑sciences innovation.

Veeva Systems Inc. dominates cloud‑based life science software, boosting biotech efficiency and growth—stock trends, adoption, and future prospects.

Veeva Systems Inc. reported strong Q2 financial results, with a 14% increase in earnings per share, and announced a strategic partnership with Amgen to drive innovation in clinical trials, further solidifying its position as a leader in the health c…

Veeva Systems Inc. reported a 17% revenue increase to $789.1 million in Q2 2026, exceeding market expectations and solidifying its position as a leader in the health care technology sector.

Veeva Systems Inc. has seen its market position bolstered following a successful outcome for GlaxoSmithKline, prompting Raymond James to reaffirm its ‘Outperform’ rating on the company’s stock.